Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Portfolio Pulse from
Medexus Pharmaceuticals has completed an agreement to return US commercialization rights for Gleolan to NX Development Corp. Medexus will receive a per-unit amount on Gleolan sales by NXDC through June 2025, reducing its royalty payment for fiscal year 2025.
March 14, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Medexus Pharmaceuticals has returned US commercialization rights for Gleolan to NX Development Corp. Medexus will receive a per-unit amount on Gleolan sales by NXDC through June 2025, reducing its royalty payment for fiscal year 2025.
The return of US rights for Gleolan to NXDC means Medexus will no longer handle its commercialization, which could impact its revenue streams. However, the agreement to receive a per-unit amount on sales through June 2025 mitigates immediate financial impact, resulting in a neutral short-term effect.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80